Clinical Trials Browser

Stomach Neoplasms × Capecitabine × Gastrointestinal × Clear all

NCT07431281 2026-05-27

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05152147 2026-05-19

HERIZON-GEA-01

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT07069712 2026-05-18

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05702229 2026-05-14

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT07432295 2026-05-14

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

NCT04379596 2026-05-13

DG-03

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05568095 2026-05-08

STAR-221

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04034251 2026-05-05

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Phase 2 Terminated

12 enrolled 18 charts

GastrointestinalGynecologic

Adenocarcinoma, Peritoneal Neoplasms, Stomach Neoplasms

NCT07007182 2026-05-01

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05867121 2026-04-27

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Phase 1 Active not recruiting

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT03653507 2026-04-17

GLOW

Phase 3 Active not recruiting

507 enrolled 65 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04661150 2026-04-16

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Phase 2 Active not recruiting

42 enrolled 9 charts

Gastrointestinal

Stomach Neoplasms

NCT03161522 2026-04-15

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT07529613 2026-04-14

T-DXd_HER2Low

Phase 1/2 Completed

Gastrointestinal

Stomach Neoplasms

NCT07515625 2026-04-07

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2 Recruiting

GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06256328 2026-03-13

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT03221426 2026-03-09

KEYNOTE-585

Phase 3 Completed

1,007 enrolled 25 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04882241 2026-03-06

KEYNOTE-585

Phase 3 Completed

120 enrolled 17 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03675737 2026-02-27

KEYNOTE-859

Phase 3 Completed

1,579 enrolled 31 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT06532006 2026-02-27

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase 2 Active not recruiting

40 enrolled 67 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03399110 2026-01-27

XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)

Phase 3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT07315750 2026-01-21

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT03257163 2026-01-20

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT06065371 2025-12-19

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Phase 1 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06630130 2025-12-15

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT03615326 2025-12-11

MK-3475-811

Phase 3 Completed

738 enrolled 22 charts 3 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT01191697 2025-11-03

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Phase 2 Completed

37 enrolled 11 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT04363801 2025-10-09

DisTinGuish

Phase 2 Terminated

247 enrolled 38 charts

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05980481 2025-09-29

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Phase 3 Completed

Gastrointestinal

Stomach Neoplasms

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02872116 2025-08-07

CheckMate649

Phase 3 Completed

2,031 enrolled 19 charts 1 FDA

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT02205047 2025-07-31

INNOVATION

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT03153280 2025-07-08

Lithium

Phase 1 Terminated

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04963088 2025-06-26

TALENT

Phase 1/2 Completed

Gastrointestinal

Stomach Neoplasms

NCT03448835 2025-06-08

PANDA

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT06881017 2025-03-18

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT01924819 2025-03-04

TOPGEAR

Phase 2/3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT02485834 2025-01-20

FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

Phase 2 Terminated

5 enrolled 11 charts

Gastrointestinal

Stomach Neoplasms

NCT00780494 2025-01-14

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Phase 2 Completed

35 enrolled 13 charts

GastrointestinalSarcoma

Stomach Neoplasms, Gastrointestinal Stromal Tumors

NCT06730373 2024-12-31

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06748508 2024-12-27

FDZL-GC003

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Phase 1/2 Completed

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT02892123 2024-11-27

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Phase 1 Completed

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT04281576 2024-11-14

Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Phase NA Completed

Gastrointestinal

Stomach Neoplasms

NCT04933227 2024-11-14

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT04937738 2024-11-06

PECORINO

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms